The trial is expected to enroll up to 146 patients globally and evaluate OD-001 in combination with vedolizumab during a 12-week induction period, followed by maintenance with OD-001 monotherapy ...

Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced ...

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.

Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S.

In an exploratory analysis of participants with baseline NfL levels at or above the median (n=13), mean change in NfL levels was ~ 5.7 pg/mL over 12 weeks. GFAP levels were stable over the first 12 ...

Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced ...

Prodigy Silk is Kraig Labs' production arm, a vertically integrated operation that rears, harvests, and processes recombinant spider silk. The additional capital will support new capacity, strengthen ...

New UK comparative study data assessing patient preferences between trainer devices suggest EURneffy ® is viewed as less burdensome than adrenaline auto-injectors (AAIs) 1; After ...

RESTORE is a multicenter, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating the efficacy and safety of NVG-291 in adults living with chronic cervical ...

Laru-zova demonstrated a favorable safety and tolerability profile, consistent with prior trials ...

The platform uses resonant inductive power transfer technology to transfer electricity across an air gap without physical connectors. The system is designed to deliver charging power of up to 10 kW ...

Sutro Participant: Alice Yam, Ph.D. Presenter: Daniel Calarese, Ph.D. Following the event, the content will be made available in the Scientific Publications section of Sutro Biopharma’s website at www ...